BLOOD PRODUCT INDUCED IMMUNOMODULATION AND ITS CLINICAL CONSEQUENCES

[1]  H. Watson,et al.  Oesophageal Candidiasis in an HIV-Negative Individual Treated with Factor VIII Concentrate , 1992, Thrombosis and Haemostasis.

[2]  M. Wadhwa,et al.  Mechanisms of inhibition of T cell IL‐2 secretion by factor VIII concentrates , 1992, British journal of haematology.

[3]  C. Peschle,et al.  PCR analysis of HIV‐1 sequences and differential immunological features in seronegative and seropositive haemophiliacs , 1992, British journal of haematology.

[4]  W. Kreuz,et al.  Factor VIII inhibitors in haemophiliacs , 1992, The Lancet.

[5]  P. Simmonds,et al.  Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non‐virus inactivated factor VIII and IX concentrates , 1992, British journal of haematology.

[6]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[7]  P. Mannucci,et al.  Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate , 1992, Thrombosis and Haemostasis.

[8]  C. M. Steel,et al.  Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy , 1992, British journal of haematology.

[9]  K. Pasi,et al.  Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y) , 1991, British journal of haematology.

[10]  A. Rocino,et al.  The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate. , 1991, Blood.

[11]  M. Tang,et al.  CD4 Cells in HIV-1 Infected Hemophiliacs: Effect of Factor VIII Concentrates , 1991, Thrombosis and Haemostasis.

[12]  B. Autran,et al.  HIV epitopes recognized by cytotoxic T-lymphocytes. , 1991, AIDS.

[13]  P. Mannucci,et al.  Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. , 1990, The New England journal of medicine.

[14]  K. Pasi,et al.  In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity , 1990, British journal of haematology.

[15]  C. Hay,et al.  Inhibition of lymphocyte IL2‐receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs , 1990, British journal of haematology.

[16]  A. Meyer,et al.  Wound Infection Rates After Invasive Procedures in HIV‐1 Seropositive Versus HIV‐1 Seronegative Hemophiliacs , 1990, Annals of surgery.

[17]  J. Mannhalter,et al.  Modulation of human monocyte functions by factor VIII-anti-factor VIII complexes present in an affinity-purified factor VIII product. , 1990, Blood.

[18]  J. Goedert,et al.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. , 1989, The New England journal of medicine.

[19]  C. Kessler,et al.  The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. , 1989, JAMA.

[20]  P. Dilger,et al.  Inhibition of interleuk:in‐2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs , 1989, British journal of haematology.

[21]  E. Engleman,et al.  Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. , 1989, Journal of immunology.

[22]  J. Mannhalter,et al.  Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity. , 1988, Blood.

[23]  D. Aronson.  Cause of death in hemophilia a patients in the United States from 1968 to 1979 , 1988, American journal of hematology.

[24]  J. Goedert,et al.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. , 1987, Annals of internal medicine.

[25]  C. Forbes,et al.  Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. , 1986, British medical journal.

[26]  D. Brettler,et al.  Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses. , 1986, The Journal of pediatrics.

[27]  R. Cheynier,et al.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. , 1986, Science.

[28]  M. Fritzler,et al.  Natural killer cell activity from hemophiliacs exhibits differential responses to various forms of interferon. , 1986, Blood.

[29]  M. D. Williams,et al.  Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital. , 1985, Journal of clinical pathology.

[30]  R. Prescott,et al.  ABNORMALITIES OF CIRCULATING LYMPHOCYTE SUBSETS IN HAEMOPHILIACS IN AN AIDS-FREE POPULATION , 1984, The Lancet.

[31]  J. Murray,et al.  Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979. , 1983, Journal of clinical pathology.

[32]  J. Elliott,et al.  Pneumocystis carinii pneumonia among persons with hemophilia A. , 1982, MMWR. Morbidity and mortality weekly report.